What You Should Know:
– Sequel Med Tech, LLC, known for its innovative insulin delivery technology, and Senseonics Holdings, Inc., developer of long-term implantable continuous glucose monitoring (CGM) systems, announced a significant commercial development agreement.
–…
Continue Reading
What You Should Know:
– Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18…
Continue Reading
Image by freepik
What You Should Know:
– New research published in Clinical Diabetes, a peer-reviewed journal of the American Diabetes Association, reveals that patients receiving continuous glucose monitors (CGM) through durable medical equipment (DME) providers…
Continue Reading
What You Should Know:
– Glooko, a provider of integrated digital health solutions for diabetes management, has announced a significant expansion of its platform’s capabilities with the integration of Abbott’s FreeStyle Libre continuous glucose monitoring…
Continue Reading
What You Should Know:
– Sequel Med Tech, LLC, a company focused on developing cutting-edge insulin delivery technologies, has announced that its innovative twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, will be the…
Continue Reading
What You Should Know:
– Senseonics Holdings and Ascensia Diabetes Care today announced the integration of the Eversense® 365 Continuous Glucose Monitoring (CGM) System with the SweetSpot™ diabetes management platform in the U.S.
– The collaboration…
Continue Reading
What You Should Know:
– Dexcom, the global leader in continuous glucose monitoring (CGM), has achieved another groundbreaking milestone by launching the first generative AI (GenAI) platform in glucose biosensing technology, Stelo.
– The Stelo platform…
Continue Reading
What You Should Know:
– Abbott announced that its FreeStyle Libre 2 and 3 continuous glucose monitoring (CGM) systems have received FDA clearance for use during common imaging procedures, including X-rays, CT scans, and MRIs.
–…
Continue Reading
What You Should Know:
– Ascensia Diabetes Care has announced the U.S. launch of the Eversense® 365 continuous glucose monitoring (CGM) system, an advancement in diabetes management.
– Developed by Senseonics Holdings, Inc., Eversense 365 is…
Continue Reading
What You Should Know:
– A research study by CCS, a leading chronic care management company, reveals that patients receiving continuous glucose monitoring (CGM) devices through medical benefits experience superior adherence and lower costs compared…
Continue Reading
